



European Precious Metals  
Federation

European Precious Metals Federation

# Silver Work Group Conference Call

1 April 2020



European Precious Metals  
Federation

# Welcome & Introduction

# Some practical recommendations



Turn off your  
webcam



Use headphones if  
possible



Microphone on mute  
until you wish to  
speak



Submit questions or  
comments via the  
chat



# Reminder on Confidentiality and Competition law

DO	DON'T
<u>Application of competition law</u>	
Art. 101 and 102 TFEU may be applicable to the conclusion of any preliminary agreement and activities of any preliminary phase.	Don't assume that conflicts with competition law are excluded simply by the fact that the Agreement complies with the provisions of the REACH Regulation.
<u>Consultation in Matters of Competition Law</u>	
Consult an in-house legal expert or the compliance officer of your company or an external lawyer whenever there are uncertainties respecting compliance with competition law. Stop all meetings/discussions which are not in compliance with these Compliance Guidelines until a legal expert has been involved.	Don't assume that these Compliance Guidelines deal with all competition law issues exhaustively. Basically, compliance with Art. 101 and 102 TFEU can be determined only on the basis of market impact in each individual case. These Compliance Guidelines may therefore be regarded only as a means of providing general conduct recommendations.
<u>Activities in any preliminary phase and at any other stage of operation of the Consortium</u>	
Restrict cooperation within the scope of the preliminary phase to the initially defined goals and purposes of the cooperation.	Pursuant to Art. 101 and 102 TFEU, activities which have the object of the effect of preventing, restricting and/or distorting competition are prohibited within the scope of this Agreement, including: <ul style="list-style-type: none"> <li>- Coming to agreement, including arrangements or collusions, about prices, markets and customers (see Art. 101 paragraph 1 a)-e) TFEU);</li> <li>- Joint boycotting of other companies;</li> <li>- The unjustified unequal treatment of trade partners;</li> <li>- The abusive exploitation of a dominating market position.</li> </ul>
<u>Exchange of Confidential Information</u>	
Involve a Trustee for the exchange of Confidential Information.	The exchange of Information concerning market behaviour and having the object or the effect of preventing, restricting and/or distorting competition is inadmissible; in particular, this relates to : <ul style="list-style-type: none"> <li>- Production capacities;</li> <li>- Productions or sales volumes;</li> <li>- Import volumes;</li> <li>- Market shares;</li> <li>- Price policy;</li> <li>- Distribution and marketing terms;</li> <li>- Marketing strategies;</li> <li>- Information regarding the relationship with suppliers.</li> </ul>
<u>Documentation on Cooperation</u>	
Keep minutes of all meetings which detail the subject of the meeting. In case of uncertainty, have the contents of the minutes reviewed by an external legal expert prior to sending them to all parties of the Agreement. Stop all meetings which are not in compliance with these Guidelines until a legal expert has been involved.	



# Approval of the agenda

## 0. Welcome and Introduction

- Reminder on Confidentiality and Competition Law
- Approval of the agenda
- Approval of the minutes of the last meeting (8 Oct 2019) and status of action points

## 1. Silver reproductive toxicity

- EOGRTS: test design and status update

## 2. Silver read-across and TK study

- Test design and status update

## 3. Silver carcinogenicity

- Status update

## 4. CLH proposals silver nitrate and silver

- Status update and science defence

## 5. Silver advocacy

*15' Coffee break*

## 6. Silver Impact assessment

- Project update
- Status of data collection
- Preliminary findings
- Next steps

## 7. Workplan and budget 2021

## 8. AOB, next meetings/calls and closing remarks

**FOR APPROVAL**



# Approval of the minutes of the last meeting (8 Oct 2019)

Final draft minutes of the meeting on 8 October 2019, circulated on 15 October 2019

**APPROVAL OF DRAFT MINUTES**

## Status action points last meeting (1/2)

What?	Who?	Status
1 Include a RSS for AgNPs in the Ag dossier referring to ongoing EOGRTS for AgAc + ongoing TK work for read-across and submit dossier update	EPMF Sec + Ag LR	Done
2 Draft internal Gantt chart on different steps for dossier update following EOGRTS results, sequencing the updates in the most efficient way	EPMF Sec	Ongoing
3 Draft Gantt chart to highlight when Tox Experts (TE) and WG members must be available for review and commenting of the EOGRTS results and schedule regular TE meetings / calls for interim reporting / discussion of test results	EPMF Sec + Ag TE + study monitors	(timelines TBC)
4 Ask Covance to report testing outcomes in format suitable to enter into IUCLID	EPMF Sec + study monitors	To do
5 Re-discuss adjusted ppms during lactation in DRF + EOGRTS to avoid the risk of overdosing	EPMF Sec + Ag TE + reprotox study monitor	To do
6 Select elemental Ag ( $\geq$ micron-sized) and elemental nanoAg test items for TK testing	EPMF Sec + Ag TE + TK study monitor	Done
7 Discuss strategy for defence of massive Ag, considering available data on skin penetration	Ag WG	To do (when TK results available)
8 Confirm final details of the TK tissue analyses validation	EPMF Sec + Ag TE + TK study monitor	To do (after method dev.)



## Status action points last meeting (2/2)

What?	Who?	Status
9 Check which elemental Ag forms are covered exactly under the BPR / in the elemental Ag CLH proposal	EPMF Sec	<b>To do</b> (when elemental Ag CLH proposal available)
10 CLH comments: assess the potential link between the skin sensitisation classification proposal and the presence of Ni impurities	EPMF Sec	<b>To do</b>
11 Include <i>in vitro</i> skin corrosion test data in AgNO <sub>3</sub> dossier and update skin corr. classification of solid form / solutions ≥ 5% AgNO <sub>3</sub> to Cat. 1A + include evidence in CLH comments	EPMF Sec	<b>To do</b>
12 Invite possibly influential downstream users to the November DU workshop	Ag WG	<b>Done</b>
13 Indicate when WG members should be available for input on the impact assessment	EPMF Sec + EFTEC	<b>Done</b>
14 Add disilver sulphate uses to the REACH registration dossier	EPMF Sec	<b>Done</b>





# 1. Silver reproductive toxicity

## EOGRTS TP: Reminder final Decision (26 Jun 2019)

- EOGRTS (Annex X; OECD TG 443) in **rats, oral route** with the analogue substance **silver acetate (AgAc)**:
  - **10 weeks pre-mating exposure duration** for the parental (P0) generation;
  - Dose level setting shall aim to induce systemic tox at the highest dose level;
  - Cohort 1A (Repr tox);
  - Cohort 1B (Repr tox) **without extension** to mate the Cohort 1B animals to produce the **F2 generation**;
  - Cohort 2A and 2B (**Developmental neurotoxicity - DNT**) and
  - Cohort 3 (**Developmental immunotoxicity - DIT**)
- **30 months** to submit the EOGRTS test results; deadline **3 January 2022**
- *'eventual validity of the **read-across** hypothesis and grouping approach will be reassessed once the requested information is submitted'* ► stresses importance TK program (cfr. agenda point 2)
- Dose level setting: palatability + prelim study to inform on dosing for EOGRTS



# EOGRTS: test design and status update

- **Covance** (previously Envigo) selected for TK + reprotox testing



indicated capability to perform the tests + meet the TP timing

- Study monitor (SM): Lindsay Aveyard
- Study design extensively discussed by Ag TE/WG
- EOGRTS = package of 3 assays
  - 1/ Palatability study – assess palatability and toxicity of AgAc
  - 2/ Prelim EOGRTS – assess influence AgAc on reproductive performance to assist in dose selection for full study + ancillary studies
  - 3/ EOGRTS – full study to assess influence AgAc on reproductive performance



# EOGRTS: test design and status update

## Palatability study:


- Study plan **finalised**, **start scheduled 1 April**
- 14 days administration, AgAc via diet
- Dosing regime: 0 – 4 – 40 – 120 – 160 mg AgAc/kg(bw)/d  
~ **Sprando** study/**Lison** study
- Per dosing level: 3♂ + 3♀
- Daily monitoring BW, food/water consumption, clinical observations
- At termination: macroscopic pathology+organ weight, tissue fixation (abnormalities only, blood & serum sampling (test run for further testing))



# EOGRTS: test design and status update

## Prelim EOGRTS

- 1w acclim + 17w treatment – AgAc – dietary admin
  - F0: 12♂+12♀ per dose (n=120)
  - F1: 10♂+10♀ per dose (n=100)
- Control + 4 doses (dosing level *tbd*)



- ‘standard’ parameters + ancillary analysis (e.g. Ag / Se / Cu / Ceruloplasmin / Glutathione peroxidase in blood, serum and/or tissues; slides for AMG...)

cfr. ‘wish list’ – Ag TE to provide input by 3 April, SM to collate by mid April

**=> Test setup under discussion with Ag TE / SM !**



# EOGRTS: test design and status update

**Covance** - Currently **difficulties** and **unclearities** around:

- analytics package
  - ICP-MS failure at Covance
  - analytics subcontracted to Arcinova
- inter-business coordination between Covance and Arcinova
  - contract finalisation
  - information transfer
- study details
  - changing location
  - changing study timelines
  - changing study directors

**!! EPMF Sec and study monitors have been / are taking several corrective actions !!**


- **F-t-F meeting at Covance (re-set meeting)**
- **Technical and management calls**



# AgAc gut biome study – background recap


EPMF sponsored support study@UCL (Brussels)

*‘Effects of Ag on gut microbial populations / influence re indirect toxicity’*




# AgAc gut biome study – background recap

- **Ag analysis in blood:** consistent with other studies; ♀ higher BA than ♂; oral BA higher via gavage than dietary admin; saturation kinetics not achieved (exposure levels too low)



- **Ag analysis in reproductive organs (wk 10):**

- ♀: consistent with other studies
- ♂: higher than other studies



# AgAc gut biome study – AMG results


**Key question:** Ag deposition in brain/repr organs & passing Blood-Brain or Blood-Testes Barrier (B(B/T)B)? → **autometallography (AMG)** staining of brain & reproductive organs

- **AMG principle:** staining adds Ag<sup>0</sup> to spots where metals (mainly Ag in this case) are present - the technique amplifies and enlarges these spots
  - > check morphologically if Ag is present in the organs/parenchyma and the vascular system
- Meeting with Ag TE and Prof Lison UCL (25 Feb 2020)
- AMG results suggest presence of Ag deposits in the brain cells and suggest that **Ag is able to pass the BBB**




# AgAc gut biome study – AMG results


Ctl




4



40



400 mg AgAc/kg food



# AgAc gut biome study – AMG results

## Conclusions AMG slides:

- Presence of Ag deposits in the brain cells suggests that Ag is able to pass the BBB
- Dose-related Ag deposits in brain (Ag likely present as Ag selenides or sulphides)
- Presence  $\neq$  active... not sure if there is any effect associated with presence (cfr. argyria)
- Similar results observed for the testes

## Follow-up actions:

- Desktop study on Ag and Cu transport ongoing
- Neuropathologist to read brain slides blind (first HD and control to see if they can differentiate, with special attention to the hippocampal region) and see if they can find any damage
- Further neuropath investigations in reprotox studies





## **2. Silver read-across and TK study**

# Silver read-across and TK study

## Aims of TK:

- Support of reprotox assays
  - planned EPMF EOGRTS
  - read-across
  - assists the interpretation of previous key reprotox reports
- TK dataset improvement
  - first comparative TK profiling performed for ionic Ag vs AgNP vs bulk Ag
  - Unable to rely on simple modelling (bioelution etc.)
- Defence (including CLH)
  - Key argument: predicted TK differentiation for bulk Ag
  - promise to COM / ECHA for gap filling & more objective/TK information

TK **study monitor**: Mark Raffray




# Silver read-across and TK study: design

- Test design in alignment with **OECD 417**
  - Known gender differences in Ag TK => ♂ and ♀ sub-groups required (4 ♂ + 4 ♀)
  - **Dosing:**
    - Repeated dose gavage segment: 3 dose levels per test item
    - Single dose (gavage / i.v.) segment: 2 dose levels per test item
  - Ag measurements in blood and tissues
  - **Test items:** AgNP suspension, Ag microsized powder, Ag acetate, Ag nitrate
    - **AgNP:** smallest REACH registered AgNP not available; certified reference material (CRM) used instead - agpure® W10; official OECD (NM-300K silver) and BAM CRM, mean particle size 15 nm
    - **AgMP:** EPMF member material selected - high purity (> 99%), crystalline, sub-micron silver powder of highly uniform spheroidal shape, particle size 0.24-0.52 µm
- ! Proper characterisation needed to confirm suitability AgNP & AgMP for *in vivo* testing !**

# Ag TK testing

## Results AgNP/AgMP characterisation program

- Work at VITO/ECTX (finalised mid March 2020)
  - characterisation & intrinsic properties (size,  $\zeta$ -potential, contaminant ionic Ag etc.)
  - suspension characteristics (agglomeration, sedimentation behaviour) & dissolution in vehicles + evolution in time
- Vehicles:
  - 1% Methylcellulose (400 cps) for gavage
  - 5% glucose for i.v.
- Ionic Ag fraction:
  - AgNP  $\pm 5,3\%$  (as expected)
  - AgMP (dissolved in vehicle)  $\ll 0,01\%$



difference in dissolution!



# Ag TK testing

## Testing setup

- Stability AgNP/AgMP in vehicles
  - 11 days for 1% MC
  - 24 h for 5% gluc
  - DLS (dynamic light scattering) vs time

**Conclusion: stable suspensions** over time


- Dissolution ionic Ag (3 kDa filtration)
  - 1% MC:  $\Delta = 2500-3500$
  - 5% gluc:  $\Delta = 50-300$

**Conclusion: stable** over time, **much lower dissolution** for AgMP than AgNP

- Critical: suspension preparation + homogenisation → communicated to Covance!

**Worthwhile testing program!**

**Promising enabling work for in vivo TK!**



# Ag TK testing

## TK dosing regime

### Phase 1 - Single Dose (oral gavage)

Group	1	2	3	4	5	6	7	8
Compound	AgAc		AgNO <sub>3</sub>		Ag MP		Ag NP	
Route	Oral gavage							
Dose level (mg/kg)	5	175	5	125	36	1000	3.6	360

### Phase 2 - Single Dose (intravenous bolus)

Group	10	11	12	13
Compound	AgAc	AgNO <sub>3</sub>	Ag MP	Ag NP
Route	Intravenous			
Dose level (mg/kg)	1.5	1.5	20	2.5

### Phase 3 - Repeat Dose 1 (oral gavage; silver salts)

Group	15	16	17	18	19	20	21
Compound	Vehicle Control	AgAc			AgNO <sub>3</sub>		
Route	Oral gavage						
Dose level (mg/kg/day)	0	5	55	175	5	55	125

### Phase 3 (CONTINUED FROM PREVIOUS TABLE) (oral gavage; micron-sized and nanoparticulate silver)


Group	22	23	24	25	26	27
Compound	Ag MP			Ag NP		
Route	Oral gavage					
Dose level (mg/kg/day)	36	180	1000	3.6	36	360

Single dose

Repeated dose

# Ag TK testing

## TK experimental setup



## Analysis

- Ag in **blood** (up to 96h post-dosing)
- Ag in **tissue** (brain, bone marrow, small intestine, liver, spleen, ovaries, testes, uterus)
- Retain brain (1/2) and testes (1/2) for potential AMG analysis

# Ag TK testing

## TK Status update

...delayed...

- Main challenge = analytical method
  - Blood/tissue destruction protocol:
    - HNO<sub>3</sub> addition, overnight at 40°C
    - **EPMF position** (// earlier robust studies, Lison study):
      - HNO<sub>3</sub> + HCl
      - Microwave digestion (high temperature and pressure)

**AgTE position: EPMF position needs to be installed, otherwise change of CRO**

- Study plan = close to be finalised
- Timing ~ analytical progress





## **3. Silver carcinogenicity**

# SCAS carcinogenicity

## Carc endpoint coverage

- **ESTF** (~biocides): Experimental study (OECD453)
  - SZZ (Silver Zinc Zeolite) as test item
  - Test on mice and rat  
(Takizawa, 1992)



- **EPMF** Ag dossiers
  - no carcinogenicity test data
  - waiving statement based on absence of
    1. mutagenic potential (via weight-of-evidence) and
    2. reliable human data indicating any concern for carcinogenicity

# SCAS carcinogenicity testing

## History and progress so far

- KEMI (**end 2019**): request to fill carcinogenicity datagap (OECD453 study) – agreement within Biocides WG
- Meeting KEMI - ESTF (9 **Dec 2019**):
  - ESTF proposed to perform *in vivo* TK with SZZ
    - consider together with EPMF *in vivo* TK data
    - aim: investigate read-across possibility from existing carcinogenicity study with SZZ to non-zeolite materials
  - KEMI agreed
    - ESTF to submit (written) justification in Jan 2020 (EPMF contributions!)
    - KEMI to investigate if RA would be sufficiently robust once data were available
- **Jan 2020**: EPMF contacted Erik Vandeplassche (Chair Biocidal Products Committee)
  - eCA driver of the process, WG only ‘advisory role’
  - Meetings: restricted to members, accredited stakeholders as observer (not EPMF!)
  - Meeting agenda is public, minutes not
  - Suggestion to contact ESTF for info



# SCAS carcinogenicity testing

## History and progress so far

- Early **March 2020**: call EPMF – KEMI
  - KEMI not convinced on ESTF submission
  - No TK data being generated by ESTF so far
- End March: confirmation KEMI to ESTF about **preparation official request** for OECD453
  - Door for TK still open
  - 4 years for submission results (mid 2024 – time fits with deadline of BPR to finalise ongoing dossiers <end 2024!)
  - Ionic Ag test substance (Ag acetate?)

- ! **Concern from companies / TE on ESTF handling such important study**
  - **need to implement in REACH dossiers**
  - **important consequences for Ag business**



# Next steps

- EPMF Sec
  - considers **SZZ not as worst-case** test item
  - is not aware of existence **reliable TK data for SCAS**
    - read-across from SZZ to all SCAS unlikely
  - considers **need to perform new carcinogenicity test** very likely
  - considers request for '**soluble Ag compd**' as **test item** very likely
    - read-across to our REACH dossiers very likely + need to access to
- Ag WG previously agreed to closely monitor developments (via ESTF) and to **(co-)lead the carcinogenicity test** to ensure highly reliable endpoint coverage
- **Proposal to board:**
  - Create **sub-group of EPMF/ESTF experts** to discuss preparation and set-up of the study + ensure a proper communication with the different parties
  - Consider to **co-sponsor the study** (50%?), ensuring co-ownership of the data but also a leadership position on science
  - Set up the **legal framework** to co-sponsor the study and around the mechanisms of decision
  - Include a **budget of 1,5 millions € in 2021** budget (50:50 split over Ag and Ag compounds) – budget already partially available in the reserves





## **4. CLH proposals silver nitrate and silver**


## Recap CLH proposals Ag biocides reprotox (Keml / RAC)

SZZ	Repr Cat. 1B proposed, Cat. 2 agreed by RAC
SZ, SCZ	Repr Cat. 2 proposed (no RAC decision yet)
SSZHP	No Repr classification proposed
AgNO <sub>3</sub> , Ag	<b>Repr Cat. 1B</b> proposed
AgCl	Repr Cat. 1B?

**!! Consequences Repr 1B classification: no consumer uses & meeting SVHC criteria (~authorization)!!**

# Silver CLH: the process

Unclear timing!





European Precious Metals  
Federation

## **5. Silver advocacy**

# Impact on Advocacy first Milestone

**Success: Commission and ECHA agree to delay public consultation start**

**Timing: now to end Q2 2020?**

## Leverage scientific concerns

### Play to DG ENV and ECHA concerns

- Continue informal discussions

### Place on public record state of science

- Independent article on science around silver for placement in peer review journal

### Scientific symposium (2020)

- Symposium on first public results, TK results
- Trade media outreach

### Depending on when Kemi resubmits its CLH dossiers, re-engage with interested MSCAs from TP phase to encourage to submit to public consultation

- Reach out to PL, IT, FIN, DE

### Depending on when Kemi resubmits its CLH dossiers, Activate third country regulators to submit to public consultation

- Outreach to CH, NO, India, NZ, RSA, US, OECD

## Activate value chain

### Establish coordination mechanism with DUs

- Regular update calls scheduled
- Online Platform

### Promote broad participation in public consultation

- Prepare template for public consultation responses

### Prepare for joint outreach to MSs in next phase

- Map political and economic footprint – create joint DU/Silver teams
- Prepare materials pack for advocacy use by all actors (Strat on page, Messages, Q&A, Standard Deck, Summary of SEA)

## Elevate to political level

### Take the pressure off BPR - TBC



- Find policy dissonance/application that is under threat of interest to DG SANTE
- Outreach to DG SANTE hierarchy

### Underline benefits of silver

- Create visual representation of contribution of silver to VdL/European Green Deal political agenda
- Outreach programme to incoming cabinets around critical applications/positive policy agenda
- Outreach to MEPs as part of MetalsWithAmbition weeks



# Silver and Green Deal





## **6. Silver Impact Assessment**

# Impact Assessment of silver and silver compounds

Silver Work Group conference call / 1<sup>st</sup> March 2020

Rohit Mistry; Adams Koshy;  
Thea Sletten; Oliver Pilkington

---


# Agenda

1. Project update
2. Status of data collection
3. Next steps

## Project update: Reminder of work

- **Primary objective:** produce an impact assessment
  - The introduction of a harmonised classification of Repro. 1B for silver and silver compounds
  - To understand the potential impacts on producers and uses of silver and wider EU society prior to any further regulatory actions
- **Approach:** sector-specific approach to assess the socioeconomic impacts of the classification
- **Timeline:** October 2019 – July 2020

## Project update – Current status



\*Slightly later finish to project to reflect leaving survey open longer than planned

# What input do we need from you?

## Task 2

**Dec 2019 - April 2020**

- ~~1. Two companies~~ to pilot test our survey and interview questions (Dec)
- 2. All companies / associations** to fill in our survey (Jan-Mar)
- ~~3. 10 companies / associations~~ to take part in an interview (Jan-Mar)

## Task 3

**March - April 2020**

- 4. All companies / associations** respond to queries we may have on your survey responses
- 5. 10 companies / associations** to confirm interview reports

## Task 5

**May/June 2020**

- 6. All companies / associations** to read the specific chapter on your sector
- 7. All companies / associations** to provide feedback at sector webinar and/or in writing

## Information request



**Industry  
Survey -**


*Ongoing: deadline  
extended to (latest) mid-  
Apr 2020*

**Interviews**

*All webinar  
interviews  
completed*

## Overview of survey responses

**77**  
questionnaire  
responses




\*Includes responses from DUs manufacturing silver substances (e.g. silver nitrate)

Responses currently being reviewed and follow-ups ongoing.


# Characteristics of respondents

### Role within supply chain



Note: Many companies identify themselves as more than one role.  
N= 77 organisations.


### Number of questionnaire responses



N= 77 organisations.

# Overview of DU responses

Number of DUs respondents that use a silver substance in..



Note: Downstream users can use silver substances for more than one use.

N=66 organisations

## Overview of interviews

**8 webinar  
interviews + (\*)  
2 collated  
written  
responses**

- Manufacture of silver and silver compounds (including recycling)
- Manufacture of other chemical compounds (including catalysts)
- Photography
- Medical sector devices
- Other industrial uses – batteries
- Jewellery and silverware
- Aerospace
- *Cosmetics\**
- *Electronics\**

All draft interview reports to be sent for review by interviewees by w/c 6<sup>th</sup> April.

## Overview of data

Number of responses do not necessarily mean complete responses

### Volumes of silver

**Good** information from questionnaires

### Market information

**Mixed** information from interviews - further information to be collected from sector groups and Silver Institute

### Uses and functions

**Very good** information from questionnaires and interviews

### Alternatives

**Good** information from questionnaires and interviews

### Exposure

**Mixed** information from questionnaires and interviews

### Legislation

**Limited** new information

### Impacts

**Mixed** information across questionnaires and interviews

# Key gaps

## Gaps

Further information required on all uses on impacts of proposed classification

Responses for: catalysts, mirrors, photovoltaics

Market information

## Approach

eftec following up with individual respondents and sector associations for more data

Survey to remain open until mid-April to try to get more responses for these sectors

Further review of publicly available market information planned, follow-up with sector associations, and the Silver Institute

## Next steps (over next few weeks)

- **Not too late to complete questionnaire** – further responses welcome whilst we are still validating responses already received.
- **Finalise interview scripts** – Thank you for all those that took part in interviews and/or provided collated written responses from several companies in your association. Several draft report sent out and the rest will be sent out soon to interviewees for final approval.
- **Validation of questionnaire responses** - Thank you for all those that provided completed questionnaires. We will be going back to most respondents either with clarification requests or seeing if they can fill in any bits of the questionnaire they didn't complete.
- **Questionnaire summary stats** – Responses by sectors & the quality of the data
- **Agree with EPMF secretariat the 8 sector specific chapters** – Final decision on sector specific chapters to be agreed with EPMF once questionnaire period is officially closed. Balance to be agreed based on quality & volume of data gathered and importance of highlighting the sector to target audience.

## Next steps (May – June)

- **Manufacture of silver and silver compounds chapter** – First chapter to be completed – Expected to be ready by Mid May – Webinar to be scheduled later in late May to discuss chapter.
- **Downstream uses of silver and silver compounds chapters** – To be completed in June - sector webinars to be scheduled in late June- early July to give sectors time to read their chapter in advance.

### Likely content of each DU chapter:

- Known silver substances used
- Sector specific uses & volumes
- Technical function(s) of silver / importance of their use
- EEA and Swiss markets at risk
- Assessment of possible alternatives to silver
- Additional sector-specific legislation triggered
- Most likely response(s) to proposed Repr 1B classification
- Costs of proposed classification
- Benefits of proposed classification (qualitative only)

## Next steps (July-Aug)

- **Finalise sector specific chapters** – Reflecting on all feedback received
- **Aggregated impacts chapter** – impacts collated accounting for all sectors affected
- **Aggregated impacts chapter webinar** – All sectors welcome to take join
- **Draft report**
- **Final report**

## Report outline

### Executive summary

1. Introduction
2. Method
3. What are silver and silver compounds
4. EEA & Swiss market
5. Sector/use 1 specific chapter
6. Sector/use 2 specific chapter
7. Sector/use 3 specific chapter
8. Sector/use 4 specific chapter
9. Sector/use 5 specific chapter
10. Sector/use 6 specific chapter
11. Sector/use 7 specific chapter
12. Sector/use 8 specific chapter
13. Aggregated impacts
14. Summary and recommendations
15. References

# Thank you

 Adams Koshy / [adams@eftec.co.uk](mailto:adams@eftec.co.uk)

 Rohit Mistry / [rohit@eftec.co.uk](mailto:rohit@eftec.co.uk)

+44 (0) 20 7580 5383

 @eftecUK





## **7. Workplan and budget 2021**

# Draft Budget 2021

	2021 draft budget	FTE
<b>1. Ag metal (including nano)</b>	<b>1.011.974 €</b>	<b>0,7</b>
1.1 REACH registration	0 €	
1.2 REACH dossier maintenance	805.000 €	
1.3 REACH evaluation	0 €	
1.4 REACH classification & labelling	60.000 €	
1.5 REACH authorisation	0 €	
1.6 Internal and external fixed Scientific Managers	136.174 €	
1.7 IUCLID IT hosting system	400 €	
1.8 Knowledge Management tool + hosting	400 €	
1.9 Science budget	10.000 €	



# Draft Budget 2021

	2021 draft budget	FTE
<b>2. Ag compounds</b>	<b>1.046.974 €</b>	<b>0,7</b>
2.1 REACH registration	0 €	
2.2 REACH dossier maintenance	840.000 €	
2.3 REACH evaluation	0 €	
2.4 REACH classification & labelling	60.000 €	
2.5 REACH authorisation	0 €	
2.6 Internal and external fixed Scientific Managers	136.174 €	
2.7 IUCLID IT hosting system	400 €	
2.8 Knowledge Management tool + hosting	400 €	
2.9 Science budget	10.000 €	





## **8. AOB, next meetings/calls and closing remarks**

## Next EPMF B2B meetings:

**Autumn : 6-7/10/2020, Brussels**



# THANK YOU

[www.epmf.be](http://www.epmf.be) | [info@epmf.be](mailto:info@epmf.be)

Avenue de Broqueville 12, B-1150 Brussels  
+32 (0)2 761 01 00